argenx SE Investor Relations Material
Latest events
Q1 2025
argenx SE
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from argenx SE
Access all reports
argenx SE is a biotechnology firm based in Amsterdam, the Netherlands, specializing in the development of innovative therapies for autoimmune diseases. The company has developed a range of antibody-based medicines focusing on severe autoimmune conditions. Its flagship product, efgartigimod, targets various autoimmune disorders including myasthenia gravis and immune thrombocytopenia. argenx SE also collaborates with several partners to expand its research and development capabilities in immunology and oncology, highlighting its engagement in strategic alliances to advance its pipeline of therapeutic antibodies. The company is headquartered in Amsterdam, the Netherlands, and its shares are listed on the NASDAQ.
Key slides for argenx SE
43rd Annual J.P. Morgan Healthcare Conference
argenx SE
FDA Announcement
argenx SE
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
ARGX
Country
🇧🇪 Belgium